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Background: Specialized drug treatment courts are a central part of drug-related policy and programs in the United
States and increasingly outside the U.S. While in theory they offer treatment as a humane and pragmatic alternative to
arrest and incarceration for certain categories of drug offenses, they may exclude some forms of treatment–notably
methadone maintenance treatment (MMT). We sought to understand from the perspective of treatment providers
whether this exclusion existed and was of public health importance in New York State as a case example of a state
heavily committed to drug courts and with varying court-level policies on MMT. Drug courts have been extensively
evaluated but not with respect to exclusion of MMT and not from the perspective of treatment providers.
Methods: Qualitative structured interviews of 15 providers of MMT and 4 NGO advocates in counties with diverse
court policies on MMT, with content analysis.
Results: Courts in some counties require MMT patients to “taper off” methadone in an arbitrary period or require that
methadone be a “bridge to abstinence”. Treatment providers repeatedly noted that methadone treatment is
stigmatized and poorly understood by some drug court personnel. Some MMT providers feared court practices were
fueling non-medical use of prescription opiates.
Conclusions: Drug court practices in some jurisdictions are a barrier to access to MMT and may constitute
discrimination against persons in need of MMT. These practices should be changed, and drug courts should give high
priority to ensuring that treatment decisions are made by or in close consultation with qualified health professionals.
Keywords: Drug courts, Methadone, Buprenorphine, Criminal law, IncarcerationBackground
Addiction to opiates is a significant public health prob-
lem in the United States. An estimated 620,000 persons
used heroin at some time in the previous year in 2011
compared, for example, to 373,000 in 2007 [1]. The
number of persons estimated to be dependent on pain
relievers–mainly opiates–increased from 1.5 to 1.8 mil-
lion from 2002 to 2011, representing the second most
prevalent drug dependence after marijuana, according to
the U.S. government’s assessment [1].
Decades of research and practice have established that
opioid dependence can be treated successfully and cost-
effectively. Maintenance (continuous) therapy using
methadone, an opioid agonist, has been used in the U.S.* Correspondence: hollycatania@yahoo.com
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article, unless otherwise stated.since the 1960s [2]. Methadone maintenance therapy
(MMT) is recognized by the U.S. Institute of Medicine
as well as by the World Health Organization (WHO) to
reduce cravings for illicit opioids, reduce crime linked to
drug use, reduce deaths from overdose, reduce HIV risk
behaviors, and help patients stabilize their lives and sus-
tain productive activity [3,4]. Since 2002, buprenorphine
has also been authorized for treatment of opioid depend-
ence in the U.S. and is in wide use [5]. Methadone and
buprenorphine are included for their therapeutic use on
the WHO Model List of Essential Medicines [6].
In spite of the strong scientific evidence base for it, as
of 2008 only an estimated 10 percent of those who could
benefit from it had access to MMT [7]. This access is
hampered by many factors, including the failure of pub-
lic and private insurers to cover this treatment [8,9]; theentral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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served in a specialized facility every day [9]; the lack of
providers or nearby providers [9,10]; the lack of avail-
ability of opioid dependence therapies in U.S. prisons
and pretrial detention facilities [11,12]; and resistance of
local authorities and citizens to having methadone
clinics in their neighborhoods [13].
Another factor is looming large as a determinant of
access to opioid dependence treatment in the U.S.–the
rapid proliferation of drug courts. As of June 2013 there
were 2734 drug treatment courts in the 50 states and U.S.
territories [14], up from only one in 1989 and 665 in 2000
[15]. The National Association of Drug Court Profes-
sionals, which is part of the federally funded National
Drug Court Institute, promotes the establishment of drug
courts and other “problem-solving” courts across the U.S.
[16]. U.S. officials also promote the drug court model
heavily outside the U.S. [17], as also observed by one of
the authors, JC, who was present as U.S. drug control pol-
icy officials participated in the National Association of
Drug Court Professionals and UN Office on Drugs and
Crime’s side event, “Alternatives to incarceration: provid-
ing health-based services for drug-dependents in the crim-
inal justice system” at the annual session of the UN
Commission on Narcotic Drugs, 13 March 2013. At least
15 countries have drug courts along the lines of the U.S.
model [18].
While drug courts’ policies and practices are not uni-
form even within the same state, they generally share
the objective of diverting non-violent drug users from
prison into treatment for drug dependence [19]. Most
drug courts require patients in court-mandated treat-
ment to be followed closely by the court, including fre-
quent urinalysis for drug testing and “non-adversarial”
appearances before a judge.
U.S. drug courts have been widely evaluated with re-
spect to rates of recidivism and “graduation” from treat-
ment and recidivism [20,21], but not with regard to
patterns of or access to treatment for opioid depend-
ence. While drug courts in theory could facilitate access
to opioid maintenance therapy, the available survey data
indicate this is not the case. Of U.S. counties surveyed in
2001, 20 percent said that their drug courts prohibit any
kind of medically assisted treatment including MMT, 61
percent said medically assisted approaches were limited
or were offered only for a period specified by the court,
and 19 percent had no policy [22]. A more recent survey
to which 103 drug courts responded indicated that 50
percent allowed no MMT or other opiate agonist medi-
cation under any circumstances, and 34 percent allowed
MMT in some circumstances, including when defen-
dants were already methadone patients [23].
In California in 2000, a drug court judge who believed
that methadone fails to “break the cycle of addiction”required a defendant to stop MMT against the man’s
wishes and against the advice of his treating physician.
The defendant died two months later of a heroin over-
dose [24]. Information on such cases is difficult to col-
lect since persons needing methadone who may be
denied access to the courts are often lost to follow-up.
The purpose of this paper is to investigate in another
U.S. state, New York, the practice of drug courts with
respect to MMT and the impact of those practices on
access to MMT. Few evaluations of drug courts have in-
cluded the perspective of providers of treatment ser-
vices, as this study has done. We sought to investigate
treatment providers’ understanding of drug courts’
MMT policies and whether MMT providers were regu-
larly consulted by drug court personnel in the dispos-
ition of cases of defendants with opioid dependence.
Methods and setting
The State of New York was chosen for this work because
it has the second largest drug court presence in the
country after California, with 148 drug courts of various
kinds in operation as of May 1, 2013 [25]. As of 2010, all
62 New York counties had a drug treatment court ex-
cept the county that contains only state forest land [26].
In 2009, the number of participants in drug court pro-
grams averaged 7253 per month [26]. Of these, 22 per-
cent had opiates as their drug of choice [26].
We intended to interview MMT providers in jurisdic-
tions with varying drug court policies with respect to
MMT and to include the largest urban areas in the state,
but we were unable to visit all counties with MMT pro-
grams and so reviewed information available on MMT
practices. Few courts stated their policies in publicly
available documents, and we found it was not easy to
get this information from court coordinators on the tele-
phone. The only readily available information on MMT
policies of drug courts in New York was from a 2003
survey, indicating that three of five counties in New
York City (Manhattan, Brooklyn and Queens) excluded
MMT unless patients withdrew from methadone in a
period fixed by the court; courts in Erie County (includ-
ing the city of Buffalo) stated that they followed the rec-
ommendations of treatment providers; and courts in
Suffolk County (Long Island), Onondaga County (home
of Syracuse) and Bronx County said they did not require
methadone abstinence for participation [27]. Among the
few courts with public statements of their policies were
the Manhattan and Brooklyn drug courts, which stated
their MMT policies in participant handbooks.
The authors interviewed 15 treatment providers in the
following New York counties, which represented a range
of stated policies on MMT: Brooklyn (Kings County),
Manhattan (New York County), Bronx, the counties of
the judicial Western District (Erie, Allegany, Wyoming,
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Onondaga, Nassau (Long Island), and Albany. One of the
persons interviewed was also in the process of starting a
new methadone service in upstate Jefferson County.
Treatment providers were identified through the registry
kept by the federal Substance Abuse and Mental Health
Services Administration (SAMHSA). Of the treatment
providers interviewed, six were directors of clinics, and
the others were senior clinic staff members. In counties
outside New York City, methadone clinics are few and are
well known. Some of the clinics also provided buprenor-
phine, but the majority clientele for all facilities included
in the study were methadone patients. As buprenorphine
is mostly prescribed by individual practitioners and not
through special stand-alone facilities, we did not attempt
to sample the many providers of buprenorphine mainten-
ance therapy in the state.
For clarification of drug court policies, two drug court
coordinators–full-time staff members of drug treatment
courts–and one sitting drug court judge were also inter-
viewed. We also spoke with representatives of four non-
governmental organizations that have studied drug court
practices from a human rights or legal service perspec-
tive and have testified on drug courts at public hearings
in the state legislature.
The questionnaire used for treatment providers is
shown in the Appendix. Questionnaires for NGO staff
and drug court personnel were similar. Questions were
asked in an open-ended way. Interview notes were tran-
scribed and content analysis using NVivo was planned,
but in general the longer narratives that we anticipated
did not materialize as in some jurisdictions, there was
not extensive interaction between the drug courts and
treatment providers. We analyzed transcripts with re-
spect to the key questions of whether MMT was permit-
ted as a court-mandated therapy, whether a mandatory
tapering-off period was imposed, and the degree to
which treatment providers or other specialized health
professionals were involved in drug court decisions
about mandated treatments. The few other themes that
emerged are noted in the results.
It was the intention of the authors to interview metha-
done patients with drug court experience, whom we
planned to identify with the collaboration of treatment
providers and seek their informed consent to be inter-
viewed. In the end, most of the stories of patients we
heard were of persons excluded from drug courts, and
the persons in question could not be found because they
were unable to continue in supervised treatment. As a
result, we spoke to only two patients, one in Brooklyn
and one in Nassau County, and the director of a national
patient advocacy group based in New York.
Buprenorphine maintenance is also offered by some meth-
adone maintenance providers. However, buprenorphinetreatment, unlike methadone, can be provided for opioid
dependence maintenance therapy in a physician’s office ra-
ther than in specialized facilities where patients have to
present themselves every day. As a result, most MMT pro-
viders are dealing mostly with methadone. MMT pro-
viders are readily identifiable, unlike the many private
physicians who provide buprenorphine. For this reason,
buprenorphine is not a principal focus of this study.
The research protocol and questionnaires were ap-
proved by the Institutional Review Board of the
Columbia University Medical Center where one author
(JC) was a faculty member at the time of the research.
Results
Policies and practices of the courts
In our sample, only one court (Bronx County) had a
clear practice of welcoming persons already receiving
MMT and including MMT as an option for court-
referred treatment. Albany County was characterized by
treatment providers as having zero tolerance for metha-
done; all MMT patients and persons who wanted to re-
ceive methadone or buprenorphine as court-mandated
therapy were excluded.
The Manhattan and Brooklyn drug courts, among the
largest in the state, required any existing methadone pa-
tients before the court to withdraw from MMT. The two
policies, according to their respective handbooks, are the
same [28,29]. To participate in the drug court, metha-
done patients must agree to participate in a phased with-
drawal from MMT, of which the first phase includes
demonstrating “abstinence from all other substances”,
receiving a methadone dose reduced by half, and having
four months “sanction-less time”. The second phase is
complete “detox from methadone” as well as abstinence
from other substances and unspecified “accumulated
drug-free time” of which the duration depends on the
offense with which the person is charged.
The Western District, including eight counties and the
city of Buffalo, which reportedly followed the guidance
of treatment providers, was typical of those districts with
a general policy of allowing MMT only for a fixed period
as a “bridge to abstinence”. The Western District was of
particular interest because a leading drug court judge in
the district, the Hon. Robert Russell, had been board
chairman of NADCP, which has a resolution on the ben-
efits of MMT not as a bridge to abstinence but for what-
ever period is needed [30]. Asked about the difference
between the 8th District’s policy and the NADCP policy,
Judge Russell asserted that “expressing the aspiration
that all people will be drug-free” is not counter to the
spirit of the NADCP policy.
In the Bronx, where the drug court welcomed metha-
done patients, treatment providers noted, however, that
the position of the drug court was undermined by the
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operating in the criminal courts, Treatment Account-
ability for Safer Communities (TASC)a. TASC is meant
“to integrate alcohol and substance abuse treatment into
justice processing to provide continuous treatment and
supervision for substance-involved justice populations,
and there is a large TASC-supported program in the
Bronx [31]. According to treatment providers, persons
receiving services from TASC-supported community or-
ganizations are prohibited from MMT. Treatment pro-
viders elsewhere in New York City also reported that
TASC programs’ intolerance for MMT was a problem
for their patients.
It was predicted by state lawmakers that the reform in
2009 of New York’s strict drug laws – known as the
Rockefeller drug laws–would lead to an expansion in de-
mand for participation in drug treatment court pro-
grams [32]. Treatment providers with experience before
and after the reforms were asked whether they perceived
that the reforms were associated with a greater oppor-
tunity for opioid-dependent defendants in criminal and
drug courts to be diverted to community-based MMT.
None reported evidence of any increase in referrals to
MMT by the courts.
Obligatory rapid tapering as a medical concern
MMT providers in most counties expressed concern
about the widespread idea in drug courts that MMT is
meant only as a bridge to abstinence–i.e. that treatment
cannot be maintained over a long period or indefinitely.
Treatment providers were especially concerned about
court orders for abrupt “tapering” to abstinence for per-
sons already in MMT. Some treatment providers, in-
cluding in Manhattan and Brooklyn, reported that they
and their staff spent a great deal of time fighting these
orders. Case by case, they mobilize doctors’ statements
and advocate with court officials. For some, this is a
major burden on their staff that has grown with the
prominence of the drug courts. Also of concern was the
courts’ usurping the role of the treating physicians in de-
ciding when patients should stop taking their medication
as prescribed.
Some providers said that they manage to win these ar-
guments at least some of the time, and the fight, though
time-consuming, is worth it to give patients access to
care they need. Others indicated that they know they
can’t win and have largely given up. A treatment pro-
vider in Albany County said that his clinic even had the
support of the Albany City Police in advocating for
MMT, but the court would not entertain this possibility.
Treatment providers asked to explain why they thought
the drug courts did not tolerate extended MMT attrib-
uted these attitudes to the personal biases of judges and
drug court coordinators. “Methadone always has thisstigma associated with it”, said one provider. “People
can’t think of it as medicine”.
We heard from some treatment providers that MMT
patients and potential patients who wanted to be in the
drug court or in a TASC program were finding alterna-
tive ways to get the opioids they needed. One provider
told us: “People are finding ways to get around the
courts’ methadone prohibition by getting prescriptions
for short-acting analgesics like oxycodone. The judges
allow those prescriptions, but not methadone or bupre-
norphine. We’re seeing patients come back to the
methadone clinic after going through these court-
mandated programs for help with getting off the pre-
scription drugs. Addiction to prescription drugs is one
of our biggest problems”.
Upon referral from a treatment provider, we inter-
viewed a woman aged 33 years who had come to drug
court after being arrested for felony drug possession.
Like all other defendants in New York, to be eligible to
participate in drug court she was required to enter a
guilty plea to the original criminal charge and in her
case faced a mandatory 5-7-year prison sentence if she
failed to complete the court’s requirements. She had a
history of opioid dependence but found, while in drug
court, that buprenorphine maintenance therapy was ef-
fective for her and enabled her to keep a job. Nonethe-
less she was required by the court to be “clean”–that is
to stop taking buprenorphine – within 45 days before
she could “graduate” from drug court. She was super-
vised by four different judges who cycled through the
court over 18 months, and completed a six-month stay
in a residential treatment facility, followed by a year of
frequent urine toxicology tests on demand. She told us:
“I had to leave my job every time they called me in for a
tox test. They would call me at 9:00 or 9:15 in the morn-
ing and demand that I be at the court by 4:00 or 5:00
that day”. She had a supportive employer and social net-
work and managed through remarkable personal initia-
tive to stop buprenorphine therapy abruptly for the
required period so that she could graduate from drug
court. She said: “I want to take the medication more
than I want to get high. I don’t want to live like that any-
more and I will go back into treatment as soon as my
case is over”.
Waiting lists
Treatment providers in upstate counties reported that
there were waiting lists for places in MMT programs,
averaging several months. The number of MMT pro-
grams and places within programs is restricted by state
and local regulations and affected by stigma and com-
munity resistance, resulting in demand far outweighing
availability. In Onondaga County, treatment providers
could sometimes reserve a few spots for people referred
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not at all possible in other upstate counties. As treat-
ment providers noted, even if the courts were friendlier
to MMT, waiting lists would be an impediment unless
there were assistance from the state enabling clinics to
expand or to retain slots for court-referred patients. One
director said to us: “I have 100-150 people waiting to get
into treatment on any given day. How can I bump some-
one who’s committed a crime ahead of them?” Existing
MMT patients who find themselves in the drug court
would presumably not face this barrier, though in some
jurisdictions they would face arbitrary “tapering off”
deadlines.
Communication between courts and treatment providers
Treatment providers reported a variety of models of
regular communication or contact between themselves
and drug court personnel. In the Western District, treat-
ment providers may choose to station staff members at
the courthouse on the days the drug treatment court is
in session. Health or social service staff who are present
are invited to help evaluate the treatment possibilities
for drug court participants. Treatment providers in
Onondaga County said they had regular meetings with
drug court personnel. In other counties, MMT providers
reported that they did not generally have contact with
drug court staff unless they needed to go to court to
argue on behalf of patients. In one of the larger counties,
a provider who has worked at the same MMTP since
1970 told us: “It used to be if a judge ordered a person
into MMT, we’d go back to court and fight that. Now
we’re left out. We need a single system where MMT is a
part of the treatment options. With drug courts, the
choice is taper or jail. The science doesn’t count”. An-
other said: “It varies from jurisdiction to jurisdiction. We
see typically 5-10 people a year forced by the courts to
reduce their [methadone] dose to zero”. A provider in a
smaller county recounted two recent cases of patients
being forced to stop taking their methadone by the
court: “A patient in her mid 20’s, doing well in MMT
was ordered by the judge to stop taking her methadone.
She was facing a lot of jail time and somehow managed
to do it long enough to graduate the drug court pro-
gram. She went back into MMT when she got out. An-
other patient in a different county was ordered to stop
MMT and we don’t know what happened to him. We
lost contact”. He added: “We don’t have the staff to
fight those battles in court like the bigger MMTPs in
the City”.
A few said that they invited drug court personnel to
visit their facilities but the invitations were not accepted.
One provider who has worked in MMT for over forty
years said: ‘A few years ago we invited drug court staff to
visit our program. They sent their social service peopleto present to us what they do, but it’s the judges and
prosecutors who won’t allow MMT in their program”.
Another provider told us: “We do trainings for the
courts at the judges’ request. There’s no hierarchical
structure controlling the judges and they have very little
knowledge of MMT”. The Western District was excep-
tional in that when the drug court was established, the
judge convened a meeting with treatment providers, in-
cluding the methadone clinic staff in the jurisdiction.
One legal advocate we interviewed had this to say
about the relationships between providers and the drug
courts: “Treatment providers should be considered the
fourth leg of the stool…The drug courts have no rules;
the judges make their own rules. The treatment pro-
viders need to better understand the criminal justice sys-
tem and that criminal defense lawyers are natural allies.
There’s undue deference to prosecutors and judges and
so few defense lawyers understand the literature, science
and research that supports their arguments”.
Methadone for detainees
Methadone treatment is generally not available to per-
sons in jails and prisons in New York, except in Rikers
Island, New York City’s main jail. Some of the upstate
treatment providers reported that they are sometimes
able to get permission from the drug courts for metha-
done to be brought to existing patients who are in pre-
trial detention while they are under orders to “taper”
and eventually cease methadone treatment.
Discussion
The research newsletter of the National Association of
Drug Court Professionals (NADCP) boasts: “From their
inception, Drug Courts embraced science like no other
criminal justice program. They endorsed best practices
and evidence-based practices…” [21]. The MMT policies
and practices of drug courts in several New York coun-
ties embody just the opposite: a rejection of science and
scientifically sound best practices and raise serious ques-
tions about medical ethics. Court-ordered forced with-
drawal from MMT and allowing methadone and
buprenorphine therapy only as a “bridge to abstinence”
are contrary to agreed national and international best
practices and are a disservice to people who may benefit
from the courts but who also benefit clinically from
MMT. As noted by the World Health Organization, a
strong body of research supports the conclusion that ar-
bitrary limitation of the period of MMT is clinically
counter-indicated [4]. The experience of treatment pro-
viders in the state indicates that these policies under-
mine the ability of the courts to serve many of the very
persons they were designed to serve.
The practices documented here run contrary to those
of bodies with the mandate of guiding and supporting
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association supported heavily by federal agencies, pub-
lished a resolution noting that drug courts should not
“impose blanket prohibitions against the use of [MMT]
for their participants” and that court decisions in this re-
gard should be based on “particularized assessment in
each case” [30]. An earlier position paper by the Na-
tional Drug Court Institute, the “professional services”
arm of NADCP, adopted a position statement that
methadone patients “should not be required to withdraw
from a medication that improves their lives” any more
than people who need them should be forced to with-
draw from treatment for cardiovascular conditions (This
statement no longer appears on the NDCI web site but
is reproduced by Parrino in 2003) [33]. Allowing metha-
done therapy only for arbitrarily specified periods defies
the accepted evidence that continuity of MMT over a
long period and even indefinitely is well indicated for
some patients [4]. A more recent “best practices” docu-
ment of NADCP notes that in view of “numerous con-
trolled studies” showing “significantly better outcomes”
associated with methadone and buprenorphine therapy,
“a valid prescription for such medications should not
serve as the basis for a blanket exclusion from the Drug
Court” [34].
In 1997, the National Institutes of Health convened a
consensus panel that strongly recommended greater ac-
cess to MMT for people who need it. The panel stressed
that “[a]ll opiate-dependent persons under legal supervi-
sion should have access to methadone maintenance ther-
apy, and the U.S. Office of National Drug Control Policy
and the U.S. Department of Justice should take the ne-
cessary steps to implement this recommendation” [35].
This recommendation has never been implemented on a
national or local level and is plainly not being followed
by some drug courts. Practices of the courts also fly in
the face of the recommendations of United Nations ex-
pert bodies on health and drugs as well as highly
regarded expert reviews of the Cochrane Collaboration
that have investigated both methadone and buprenor-
phine maintenance with respect to effectiveness and
safety [4,36,37]. Numerous studies have shown that
MMT keeps people with opioid dependence in treat-
ment longer than the abstinence-based therapies appar-
ently favored by some drug courts, and dropping out of
treatment is a major risk factor for overdose [38,39].
The State of New York has addressed MMT in guide-
lines on recommended drug court practices, as follows:
Methadone maintenance therapy can be a
controversial topic when utilized in the criminal
justice context…. Criminal justice professionals tend
to view methadone as another drug that is addictive
and subject to misuse…. Drug court programs shouldmake their decisions about [MMT] in the same
manner that they make other treatment-related deci-
sions, in close consultation with the treatment profes-
sionals on their team [40].
The experience of the treatment providers we inter-
viewed indicates that this guideline is being routinely
violated in some New York counties as treatment pro-
viders are not only not consulted in clinical decision-
making of the courts but are sometimes compelled to
make special appeals to the courts to respect clinical
norms and ethics. Decision-making about treatment for
drug dependence should always be made by health pro-
fessionals with specialized knowledge of treatment effi-
cacy and safety.
The perception of treatment providers in this study
that the criminal justice system was biased against
MMT was corroborated by findings of an unpublished
2011 analysis by the New York State Office of Alcohol-
ism and Substance Abuse Services (OASAS), which
found that while “40% of admissions to all drug treat-
ment services were referrals from criminal justice agen-
cies, only 5% were in opioid treatment programs
(OTPs)”. This data was presented by OASAS director
Arlene Gonzales-Sanchez at a meeting of the Committee
of Methadone Program Administrators of New York
State on May 15, 2011 in New York City in which one
of the authors, HC, was present. Treatment providers’
conclusion that methadone and other medication-
assisted treatment for opiate dependence are stigmatized
in the drug courts also corresponds to the finding of
Matusow and colleagues that MMT was sometimes seen
as just a “new addiction” to replace an old one [23].
In view of the stigmatization of methadone as a treat-
ment option and of methadone patients, the state has a
responsibility to protect access to this treatment as a
matter of legal protection of the rights of patients. The
Americans with Disabilities Act (ADA) of 1990 has been
used to defend the placement of methadone clinics in lo-
cations where residents have objected to them [41] and
to prohibit discriminatory dismissal of workers who are
methadone patients [42]. Similarly, there may be
grounds under ADA to assert that the rejection of MMT
as a treatment option for drug courts is discriminatory.
Apart from legal responsibility, the state should see as
costly and problematic the loss of persons with opiate
dependence to scientifically sound and supervised care
or their diversion to illicit use of prescription opiates.
The human cost of denial of this treatment for the indi-
viduals kept from medicines that can stabilize their lives
and keep them from having to seek drugs in illicit mar-
kets is enormous. As the World Health Organization [4]
and an important body of research [43] has shown, be-
yond its direct effect in stabilizing opioid cravings,
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employment, and be functioning members of their
communities.
D’Aunno asserts that a range of barriers to the use of
“empirically established treatment” of opioid dependence
in the US includes (1) limited resources; (2) poorly de-
signed policies, organizations structures and incentives;
(3) organizational and individual values, beliefs and
norms; and (4) individual deficits in training, skills and
motivation [44]. All of these factors may be relevant to
drug courts as a barrier to access to MMT. If limited re-
sources result in waiting lists for MMT slots, it is that
much harder to advocate for inclusion of methadone as
an option for court-mandated therapy. Policies that
incentivize exclusion of needy patients should be cor-
rected. Individual values of judges and drug court
personnel that reinforce practices that deviate from clin-
ical and scientific norms should be addressed. Where
these values are a result of inadequate technical capacity,
training should be brought to bear and measures should
be taken to ensure that qualified treatment providers
have a meaningful role in treatment-related decisions of
the courts.
Until court practices improve, it would be useful for
the state to establish a monitoring system to follow cases
of people rejected from drug court participation because
MMT is their clinically indicated or preferred treatment,
especially to ensure that these persons are able to have
access to the care they need. The federally supported
National Drug Court Institute or another body should
investigate the degree to which drug treatment courts in
the US are defying best clinical practice on MMT and
the reasons why, so as to inform appropriate policy
responses.
This study has several limitations. The inclusion of
more counties may have elicited more varied case exam-
ples. The experiences of MMT patients in the few drug
courts in which they could participate or of those receiv-
ing MMT who may have been required by the courts to
“taper off” methadone would have been a useful comple-
ment to that of treatment providers, but we did not have
the means to track down the persons whose stories were
referred to by treatment providers. The experiences of
persons for whom MMT is clinically recommended but
who wish to participate in drug courts that do not allow
MMT as a treatment option would be a fruitful topic for
further research.
Conclusion
The MMT practices of New York drug courts do not
correspond to the best practice consensus of drug court
professional associations, US government health author-
ities and international authorities. Practices such as
those documented here exclude already vulnerablepersons from humane and effective treatment to which
they are entitled.
The 2009 reform of the Rockefeller-era drug laws in
the State of New York included legislative grounding for
expanded use of alternatives to incarceration, including
court-supervised treatment for drug dependence [26].
Drug treatment courts continue to become more numer-
ous and may handle more cases as the processes associ-
ated with this reform are institutionalized. To the degree
that drug treatment courts persist in excluding MMT
from treatment options, the courts’ effectiveness will be
compromised for a key segment of the population they
were meant to serve. That this population is already stig-
matized and underserved should speak to urgency of the
need for federal, state and civil society support for im-
proving the capacity of drug court judges and staff to
adopt medically sound practices in an area of drug
dependence that benefits from decades of scientific
research.Endnote
aThe TASC program was originally established as a
federal initiative in drug legislation of 1972 under the
name Treatment Alternatives to Street Crime. The State
of New York’s Division of Criminal Justice Services now
operates task under the name Treatment Accountability
for State Alternatives. See the Division’s web site at
http://www.criminaljustice.ny.gov/opca/ati_description.htm.Appendix: Questionnaire for treatment providers
1. How long have you been working at that site (and
situation that date with respect to the start of drug
court activities in the jurisdiction)?
2. When the drug court began its activities, did
court personnel consult with you or other service
providers? If so, what form did that consultation
take? Did that consultation include discussion of
or information about medication-assisted therap-
ies? If not, were there other ways in which drug
court personnel communicated with treatment
providers, including on policies related to MMT
and buprenorphine?
3. What do you understand to be the policy of the
court on MMT and buprenorphine? In your
experience, does the policy conform to the practice
of the court? If not, in what ways do they differ?
4. Do you or others in your facility have regular
contact with court personnel, including prosecutors
and defenders? If so, describe the circumstances
under which you are likely to be in contact. If you
need to be in contact with them, are you able to be?
If not, what are the barriers to contact?
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http://www.harmreductionjournal.com/content/10/1/355. Have staff members of the court visited your
facility? If so, how many times and under what
circumstances?
6. Have you spoken to any court personnel about the
court’s policies or practices related to medication-
assisted therapy? If so, under what circumstances,
and what was the result of your interaction?
7. How would you characterize the volume of patients
referred to your facility by the courts, and how
overall has the drug court’s work changed demand
for services at your facility? Have you had to adjust
practices or procedures because of the volume or
nature of court referrals? If so, how?
8. Have drug court practices and their impact on your
facility affected access to or quality of treatment
services for patients not mandated by the courts?
9. Have you been required to assist court-ordered pa-
tients in withdrawal from MMT or buprenorphine?
Can you characterize the results of those proce-
dures in general?
10. How do you see the recent changes in NY State’s
drug laws as affecting the drug courts or your
services generally? How about with respect to
MMT and buprenorphine?
11. [If it isn’t already clear] Generally, how would you
characterize the changes that have come about in
your work because the drug courts are there? Have
they been an overall asset for your services? If so,
in what way? If not, why not?
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